Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Luveltamab Tazevibulin |
| Trade Name | |
| Synonyms | STRO002|STRO 002|STRO002|luvelta |
| Drug Descriptions |
Luveltamab tazevibulin is an antibody-drug conjugate (ADC) that consists of an anti-FolRa human IgG1 antibody linked to the anti-tubulin agent 3-aminophenyl hemiasterlin (SC209), which potentially inhibits growth of FolRa-expressing tumors (PMID: 36459691). |
| DrugClasses | FOLR1-targeted Therapy 24 |
| CAS Registry Number | 2493327-62-9 |
| NCIT ID | C158067 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Bevacizumab + Luveltamab Tazevibulin | Bevacizumab Luveltamab Tazevibulin | 0 | 1 |
| Carboplatin + Luveltamab Tazevibulin | Carboplatin Luveltamab Tazevibulin | 0 | 0 |
| Luveltamab Tazevibulin | Luveltamab Tazevibulin | 0 | 4 |
| Luveltamab Tazevibulin + Pegfilgrastim | Luveltamab Tazevibulin Pegfilgrastim | 0 | 1 |